Trial · NCT00923481
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
NCT00923481, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2012-08-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Trials, record NCT00923481. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00923481
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
- NCT number
- NCT00923481
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 37 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
- Interventions
- Fostamatinib disodium
- First posted
- 2009-06-18
- Last updated
- 2015-09-30
- Results first posted
- 2012-08-29
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate | 24 months | Response is assessed by the RECIST (response criteria in solid tumors)criteria. A complete response (CR) is disappearance of all target lesions , partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions, and stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. |
| Secondary | Number of Participants With Adverse Events | 23 months | Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate | 24 months | Participants | NUMBER | |
| SECONDARY | Number of Participants With Adverse Events | 23 months | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate | Multi-kinase Inhibitor Fosamatinib Disodium | Complete response | 0 | Participants | |
| Response Rate | Multi-kinase Inhibitor Fosamatinib Disodium | Partial Response | 0 | Participants | |
| Response Rate | Multi-kinase Inhibitor Fosamatinib Disodium | Progressive disease | 26 | Participants | |
| Response Rate | Multi-kinase Inhibitor Fosamatinib Disodium | Stable disease | 11 | Participants | |
| Number of Participants With Adverse Events | Multi-kinase Inhibitor Fosamatinib Disodium | 37 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Multi-kinase Inhibitor Fosamatinib Disodium | 37 | |
| Overall Study | COMPLETED | Multi-kinase Inhibitor Fosamatinib Disodium | 37 | |
| Overall Study | NOT COMPLETED | Multi-kinase Inhibitor Fosamatinib Disodium | 0 |
Source ClinicalTrials.gov
Adverse events95
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 22 | 37 | 57 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 23 | 37 | 66 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 29 | 37 | 77 |
| other | Alkaline phosphatase | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 17 | 37 | 32 |
| other | Allergic reaction/hypersensitivity (including drug fever) | Immune system disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | Ascites (non-malignant) | Gastrointestinal disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | Atelectasis | Respiratory, thoracic and mediastinal disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 1 | 37 | 1 |
| other | Bicarbonate, serum low | Metabolism and nutrition disorders | Multi-kinase Inhibitor Fosamatinib Disodium | 2 | 37 | 2 |
| other | Bilirubin (hyperbilirubinemia) | Investigations | Multi-kinase Inhibitor Fosamatinib Disodium | 13 | 37 | 29 |
1 to 10 of 95Source ClinicalTrials.gov
See all 95 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Multi-kinase Inhibitor Fosamatinib Disodium | ||
| Total, other adverse events | Multi-kinase Inhibitor Fosamatinib Disodium | 37 | 37 |
| Total, serious adverse events | Multi-kinase Inhibitor Fosamatinib Disodium | 11 | 37 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00923481
GET https://conductscience.org/api/trials/v1/NCT00923481/events?page=2